Pre-made Nesvacumab benchmark antibody ( Whole mAb, anti-ANGPT2 therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-373
Pre-Made Nesvacumab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Nesvacumab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Solid tumours|